Research

Hormonal

New incretin-based anti-obesity drugs (GLP-1, GIP, and triple agonists) achieve weight loss magnitudes (up to 25%) comparable to bariatric surgery by enhancing satiety and inhibiting hunger through central nervous system mechanisms.

If lifestyle changes alone aren't enough, newer incretin-based medications (like semaglutide or tirzepatide) are highly effective, offering weight loss up to 25% by targeting hunger and satiety signals in the brain. They are taken as weekly injections and are intended for long-term use, similar to how other chronic conditions are managed. While costly, they offer a non-surgical alternative with efficacy approaching bariatric surgery.

GoodSupportsHIGH confidence
With new anti-obesity drugs, it is possible to reduce body weight by up to 25%, which brings them close to bariatric surgery in terms of effectiveness. The principle through which these drugs work is either enhancing satiety or inhibiting hunger, or increasing catabolism...
Snežana Polovina et al. · Arhiv za farmaciju · 2024

Why this rating

The paper is a review citing multiple clinical trials (SURMOUNT-1, SCALE) and FDA approvals, though it notes long-term data is still emerging.

Source

Obesity management: A clinician's perspective lečenje gojaznosti iz perspective kliničara

Snežana Polovina et al. · Arhiv za farmaciju · 2024

DOI 10.5937/arhfarm74-50566

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →